PHIO: phiopharma.com Company Buyout Price
The prospects for Phio Pharmaceuticals (PHIO) rely on the efficacy of RNA interference methods in treating eye and skin pathologies, as well as patent protection. The company is currently developing oncology immunology drugs, although commercial turnover is absent due to the early stages of testing. Development is based on partnerships with laboratories and the creation of INTASYL molecules. This chart of Enterprise Value price action reflects -2.64.
Phio Pharmaceuticals Corp. (PHIO) - metric breakdowns and financial figures
Enterprise value is calculated as the sum of market capitalization and net debt. This metric reflects the actual cost of a full business buyout, accounting for all liabilities. For Phio Pharmaceuticals (PHIO), this indicator assesses the value of intellectual capital in the field of self-delivering RNA therapy. Analyzing the dynamics of the company's total value allows for the identification of overpayment for unique INT technologies. An investor determines the asset's margin of safety using this chart.